Processing...
Clinical Trials for Non-Small Cell Lung Cancer
Search
Search
There are 433 active trials for advanced/metastatic non-small cell lung cancer.
Click on a trial to see more information.
433 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with unresectable or metastatic solid tumors (including NSCLC, high-grade serous ovarian carcinoma, and uterine serous carcinoma), ECOG 0-1, and at least one accessible lesion for biopsy. Patients receive BMS-986463, a novel investigational antineoplastic agent with an undisclosed mechanism of action, as monotherapy.
ClinicalTrials.gov ID: NCT06476808
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring documented KRAS mutations (excluding prior G12C inhibitor-treated G12C tumors), including NSCLC, CRC, pancreatic, and other KRAS-mutated cancers, who have progressed after standard therapies. Patients receive PF-07985045, a novel oral KRAS inhibitor, as monotherapy or in combination with chemotherapy, targeted agents, or immunotherapy, depending on cohort and tumor type.
ClinicalTrials.gov ID: NCT06704724
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including specific cohorts for EGFR-mutant or wild-type NSCLC, HNSCC, and metastatic CRC—to investigate AZD9592, a bispecific antibody-drug conjugate targeting EGFR and cMET, given alone or in combination with standard therapies such as osimertinib or 5-FU/bevacizumab/leucovorin. Key exclusions are active ILD/pneumonitis, untreated or unstable brain metastases, active infections, or significant cardiac disease.
ClinicalTrials.gov ID: NCT05647122
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (and in some cohorts, HER2) exon 20 insertion mutations who have received prior therapy, treating them with STX-721, an investigational oral irreversible tyrosine kinase inhibitor that selectively targets mutant EGFR and HER2.
ClinicalTrials.gov ID: NCT06043817
HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors harboring a KRASG12D mutation (including NSCLC, colorectal, and pancreatic cancers) who have progressed on standard therapy and have not previously received a direct KRAS inhibitor. The trial evaluates AZD0022, a selective oral KRAS G12D inhibitor, as monotherapy and in combination with cetuximab.
ClinicalTrials.gov ID: NCT06599502
HealthScout AI summary: Adults with advanced solid tumors and good performance status are eligible for this study of BMS-986507, a bispecific EGFR/HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, in combination with either osimertinib or pembrolizumab. Key exclusions include untreated symptomatic CNS metastases, mixed SCLC/NSCLC, and severe infection or cardiac disease.
ClinicalTrials.gov ID: NCT06618287
HealthScout AI summary: Adult patients with advanced or metastatic solid tumors harboring a KRAS G12D mutation (including pancreatic, colorectal, or NSCLC), ECOG 0-1, and no prior KRAS G12D inhibitor exposure are eligible for treatment with INCB161734, a selective oral KRAS G12D inhibitor, given alone or in combination with standard therapies (e.g., gemcitabine/nab-paclitaxel, mFOLFIRINOX, cetuximab, or retifanlimab).
ClinicalTrials.gov ID: NCT06179160
HealthScout AI summary: This trial enrolls adults with advanced, unresectable or metastatic colorectal cancer, non-small cell lung cancer, non-nasopharyngeal head and neck squamous cell carcinoma, or pancreatic ductal adenocarcinoma who have progressed on or are intolerant to standard therapies. Patients will receive PF-08046052/SGN-EGFRd2, a bispecific antibody that targets EGFR and conditionally activates γ9δ2-T cells to promote anti-tumor immune responses.
ClinicalTrials.gov ID: NCT05983133
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors (including IDH-wildtype glioblastoma) harboring MTAP loss who have progressed on standard therapy, and tests TNG456, a selective, brain-penetrant PRMT5 inhibitor, as monotherapy or in combination with abemaciclib (CDK4/6 inhibitor). Eligible patients must have measurable disease, good performance status, and adequate organ function.
ClinicalTrials.gov ID: NCT06810544
HealthScout AI summary: This trial enrolls adults with advanced, unresectable or metastatic solid tumors harboring any KRAS mutation who have progressed on or declined standard therapies; patients receive ALTA3263, an oral KRAS isoform-selective inhibitor that targets both active and inactive KRAS states and is designed to inhibit over 90% of known KRAS mutations, including G12D, G12V, and G12C. Prior KRAS inhibitor therapy is generally excluded.
ClinicalTrials.gov ID: NCT06835569